Go or no go? Ozanimod and Fintepla await FDA verdicts

Go or no go? Ozanimod and Fintepla await FDA verdicts

Submitted by admin on February 26, 2020 - 10:26am
Source: 
EP Vantage
News Tags: 
Bristol-Myers Squibb
ozaminod
MS
multiple sclerosis
Zogenix
Fintepla
FDA
Headline: 
Go or no go? Ozanimod and Fintepla await FDA verdicts
snippet: 

Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's Fintepla will be scrutinised.

Do Not Allow Advertisers to Use My Personal information